Almanack Investment Partners’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Almanack Investment Partners’s Portfolio BCLI Stock Details BCLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,000	Closed	-$11.2K	–	204
2025 Q2	$11.2K	Buy	+10,000	New	+$11.2K	﹤0.01%	205

Other funds holding BCLI

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BSB

Bangor Savings Bank Bangor, Maine $1.36B AUM 19.29% 1-Year Est. Return

VWA

VSM Wealth Advisory Hunt Valley, Maryland $376M AUM 21.56% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

DJSG

D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

Almanack Investment Partners's BCLI Position: Q3 2025 in Review

Almanack Investment Partners sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2025, closing a stake of 10,000 shares — an estimated $11.2K sold.

Almanack Investment Partners first reported a position in BCLI in Q2 2025 and held it in 1 quarter. The position peaked at $11.2K in Q2 2025. 5 funds tracked by Wall St. Rank hold BCLI as of Q3 2025.

Almanack Investment Partners reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2025 after selling out during the quarter.
Almanack Investment Partners sold 10,000 BRAINSTORM CELL THERAPUTC shares in Q3 2025, an estimated $11.2K.
Almanack Investment Partners first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2025 and held it in 1 quarter.
Almanack Investment Partners's BRAINSTORM CELL THERAPUTC position peaked at $11.2K in Q2 2025.
5 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2025.

Based on Almanack Investment Partners's 13F filing for Q3 2025, filed 22 Oct 2025.